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SI Materials and Methods
Appointment 1: Consent and Questionnaires. At the first appoint-
ment, all participants provided written informed consent and
completed a battery of questionnaires, namely the Sexual Arousal
and Desire Inventory (SADI) (63), the Beck Depression Inventory
(BDI) (64), the Profile of Mood Status (POMS) (65), the In-
ternational Personality Item Pool (IPIP) (66), the Machiavellianism
inventory (Mach IV) (67), the Eysenck Personality Questionnaire
Revised (EPQ-R) (68), and the Beck Anxiety Inventory (BAI) (69).
Measurements of probability weighting were obtained by eliciting
participants’ certainty equivalents for gambles ðV20,   p,   0Þ for all
p∈ f0.05,   0.10,   0.25,   0.50,   0.75,   0.90,   0.95,   1.00g using an iter-
ative bisection procedure (70). Participants were paid the outcome
of a randomly selected trial or V15, whichever was greater.
Appointment 2: Medical Screening. At the second appointment,
participants were screened by an endocrinologist. Exclusion
criteria were active medical disease: history of stroke; epilepsy/
seizure disorder; heart attack; blackouts and episodes of un-
explained loss of consciousness; head injury if they had expe-
rienced posttraumatic amnesia greater than 24 h; loss of
consciousness for more than 1 h; significant posttraumatic se-
quelae or any evidence of cerebral damage on the computed
tomography; clinically significant abnormalities on ECG in-
cluding but not limited to conduction abnormalities; heart rate
less than 55 beats per minute as judged by the investigator; major
psychiatric illness; current intake of psychotropic medications,
benzodiazepines, or corticosteroids; current alcohol abuse/
dependency; scoring above cutoffs (8) on the Hospital Anxiety
and Depression Scale (71); any contraindication to taking testos-
terone as specified in the Summary of Products Characteristics; were
or had been taking leuprolide acetate, finasteride, spironolactone,
or cimetidine; reproductive dysfunction; previous or current
prostate cancer; elevated prostate-specific antigen (PSA) levels;
abnormal renal or hepatic function tests; sleep apnea; and pre-
vious testosterone or other androgen replacement. Three par-
ticipants were excluded because of high scores on the Hospital
Anxiety and Depression Scale and advised to attend their general
practitioner. Another participant was excluded because of low
testosterone concentrations. He was fully evaluated in regards to
his hormonal status, his repeat testosterone concentration was
within normal range, and we arranged to see him again in the
metabolic research unit in 6 mo for additional follow-up. Par-
ticipants provided blood samples for the measurement of serum
testosterone concentrations. Samples for all participants were
obtained between 8:00 AM and 9:00 AM. If candidates agreed to
participate after being found eligible, they were randomly as-
signed to the treatment (n = 21) or placebo (n = 19) group in a
double-blind procedure using an online randomization program
(https://www.randomizer.org/).
Appointment 3: Injection. At the third appointment, participants
received a single i.m. injection. Participants in the treatment
group were administered a 1-mL dose of testosterone enanthate
(250 mg; Androtardyl/Testoviron Depot), whereas participants in
the placebo group were administered 1mL saline; i.m. testosterone
enanthate is a long-acting ester of testosterone. The pharmaco-
kinetics of testosterone enanthate yields supraphysiological tes-
tosterone levels in serum as early as 2 h after injection, reaching
peak levels four to five times above basal between 8 and 24 h after
injection (72, 73).
Appointment 4: Testing. At the fourth appointment, which took
place on the following day, blood samples were collected for the
measurement of serum testosterone concentrations. These
samples were collected 17.5–20 h after the injection of testos-
terone or placebo. All participants were then given oral and
written instructions for both the modified UG task (Fig. 1)
(detailed below) and a gambling task not presented here. Par-
ticipants rated pictures of the proposers’ faces for trustworthi-
ness, dominance, frustration, angriness, friendliness, happiness,
and attractiveness and played a short practice session before
undergoing MRI. The scanning lasted ∼80 min (15 min of ana-
tomical imaging and 65 min of functional imaging), during which
participants completed both the modified UG task and the
gambling task. After scanning, participants again rated the pro-
posers for trustworthiness, dominance, frustration, angriness,
friendliness, happiness, and attractiveness and completed the
SADI, the BDI, the POMS, the IPIP, the Mach IV, the EPQ-R,
the BAI, and the certainty equivalents task. Participants also
reported whether they believed they had received testosterone
and described the effects that they would expect testosterone
administration to have on themselves and others. Participants
were paid their summed earnings from the UG task, the gambling
task, and the outcome of a randomly selected trial from the cer-
tainty equivalents task orV80, whichever was greater. The analysis
of the neuroimaging data will be presented in a separate paper.
Appointment 5: Medical Follow-Up. Finally, participants attended
the endocrinologist again 4–6 wk after the injection. A physical
examination was carried out, and blood samples were collected
and analyzed for hematocrit, lipid profile, PSA, liver, renal
profile, and hormonal status to assess any potential changes after
testosterone administration. Paired sample t tests were used to
compare the parameters at baseline and follow-up. There were
no significant changes in hemoglobin, hematocrit, total choles-
terol and its fractions, and PSA concentrations after either of the
injections. Two men enrolled in the study reported pain at the
injection sites, which fully resolved after 2 d. One participant in
the placebo group reported increased libido after injection.
Participants were paid V50 for attending this appointment.
Laboratory Measurements. Using blood samples obtained at Ap-
pointments 2 and 4, we determined serum concentrations of total
testosterone (TT) by the electrochemiluminescence immunoas-
say (ECLIA) kit on a cobas e analyzer (Roche Diagnostic Sys-
tems). Serum concentrations of sex hormone-binding globulin
(SHBG) were measured by ECLIA kit on a cobas e analyzer.
Serum albumin was measured by colorimetric assay (ALB2; cobas
e analyzer). Apparent concentrations of free testosterone (FT)
were calculated from values of TT, SHBG, and albumin using the
method described and validated by Vermeulen et al. (74). Es-
tradiol was measured by ECLIA (cobas e analyzer).
Blood samples were not obtained from two participants at
Appointment 2 and one participant at Appointment 4 because of
experimenter error. Those participants are omitted from figures
and analyses involving measurements of testosterone at the re-
spective time points.
Digit Ratio Measurements. To determine whether prenatal hor-
monal exposure was associated with the metabolism of testos-
terone to estradiol, we recalled participants to obtain their
second-to-fourth digit length ratios (2D:4D); 22 of 37 participants
complied with this request (11 placebo and 11 testosterone), and
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2D:4D was calculated from a digital photograph of the right hand
by measuring the length of the index and ring finger from the
ventral proximal crease to the tip of the finger using the GNU
Image Manipulation Program (GIMP, version 2.8.10). The rater,
who was blind to the hypothesis and the participants’ treatment,
measured 2D:4D twice with a time interval of 1 wk. These two
measurements were highly correlated (r = 0.98, P < 0.0001). The
mean value of the two measurements was used for analysis.
Questionnaires.We carried out a mixed design multivariate analysis
of variance (MANOVA) on participants’ pre- and posttask ratings
of the UG proposers’ trustworthiness, dominance, frustration,
angriness, friendliness, happiness, and attractiveness with factors
treatment, time (pre- or posttask), and proposer identity. We con-
ducted mixed design ANOVAs on participants’ scores on the SADI
(63), the BDI (64), the POMS (65), the PIP (66), the Mach IV
inventory (67), the EPQ-R (68), and the BAI (69) that were
administered at Appointment 1 (preinjection) and Appointment
4 (postinjection) to test for effects of treatment.
SI Results
Hormone Levels. As illustrated in Fig. S1, baseline serum concen-
tration levels of TT and FT in the treatment [meanTT (MTT) =
21.06 nmol/L, SDTT = 5.66; MFT = 0.48 nmol/L, SDFT = 0.12] and
the placebo groups (MTT = 20.46 nmol/L, SDTT = 5.88; MFT = 0.49
nmol/L, SDFT = 0.16) did not differ significantly (TT: Mann–
Whitney U = 162, P = 0.64, two tailed; FT: Mann–Whitney U =
169, P = 0.79, two tailed). In contrast, the postinjection testosterone
levels of the treatment group (MTT = 66.08 nmol/L, SDTT = 29.60;
MFT = 1.92 nmol/L, SDFT = 0.97) were elevated relative to those of
the placebo group (MTT = 20.44 nmol/L, SDTT = 4.10; MFT = 0.45
nmol/L, SDFT = 0.08). These differences were statistically signifi-
cant (TT: Mann–Whitney U = 4, P < 0.001, one sided; FT: Mann–
Whitney U = 0, P < 0.001, one sided), confirming the efficacy of
treatment. We also found a concomitant increase in the estradiol
levels of participants in our testosterone group (M = 185.38 pmol/L,
SD = 39.55) relative to those in our placebo group (M = 101.58
pmol/L, SD = 31.05). This difference was statistically significant
(Mann–Whitney U = 373, P < 0.001, one sided).
Treatment Selectively Increased Punishment of Unfair Offers. Our
binary probit regression of punishment yielded a positive effect of
the interaction between treatment group and offer amount,
suggesting that participants treated with testosterone were in-
creasingly likely to punish offers of increasing magnitude. We
performed follow-up analyses to determine whether this effect of
treatment was restricted to unfair offers or generous offers or if it
was common to both. By performing separate regressions of
participants’ choices in response to below- and above-average
(V6) offer amounts, we found (Table S3) that treatment influ-
enced rates of punishment for below-average offer amounts only
(β= 0.26,   SE= 0.07,   P< 0.001), with increasing punishment with
offer amount for unfair offer amounts below V6, and had no
effect on punishment of generous offers.
Beliefs About Treatment Do Not Explain Effects of Treatment. To
determine whether participants were truly blind to their treat-
ment group assignation, we examined their self-reported beliefs
regarding whether they had received testosterone or placebo; 6 of
40 participants reported believing that they had received testos-
terone. This low numbermay result from the difference between the
popular beliefs about the effects of behavior and its actual effects as
illustrated in this manuscript. Of the participants who believed they
had received testosterone, only two actually received testosterone.
As in a previous between-subjects design (40), participants’ beliefs
were not significantly correlated with the treatment that they had
actually received (r = −0.16, P = 0.32); therefore, we conclude that
participants were indeed blind to their treatment.
Although participants did not have insight into which substance
that they had received, even erroneous beliefs about treatment
can influence task responses (75). This influence is particularly
relevant in the case of testosterone, for which there exists a strong
folk belief linking it to aggression and violence (40). Importantly,
all effects of testosterone treatment that we found in our previous
analysis survive the inclusion of regressors representing treatment
belief and its interaction with offer amount. The inclusion of these
regressors also revealed several distinct effects of treatment belief
on participants’ behavior (Fig. S1).
We found that those who believed that they had received
testosterone were more likely to reject low offers (Table S1), with
a negative main effect of treatment belief and a positive in-
teraction with offer amount ðβ= 0.31,   SE= 0.13,   P= 0.02Þ. In
addition, participants’ beliefs about treatment influenced their
choices of reward magnitude (Table S4), with a negative in-
teraction between treatment belief and offer amount on reward
amounts ðβ=−0.18,   SE= 0.08,   P= 0.03Þ. Thus, when those who
believed that they had received testosterone chose to reward
high offers, they did so with rewards of lesser magnitude than
those who had believed that they had received placebo.
Hormone Levels Were Not Correlated with Digit Ratio. It has been
suggested that the rate of aromatization of testosterone into
estradiol may be related to in utero exposure to sex hormones
(38), with greater exposure to estradiol being associated with
faster metabolism of testosterone. Relative prenatal levels of
testosterone and estradiol are thought to influence the hands’
2D:4D, with a high 2D:4D indicating low prenatal testosterone
exposure relative to estradiol (76). Therefore, to test this hy-
pothesis, we tested for correlations between participants’ hor-
mone levels and their right hands’ 2D:4D. We found no
significant correlations between participants’ digit ratio and their
levels of TT ðr=−0.002,   P= 0.99Þ, the change in their TT rela-
tive to baseline measurement ðr=−0.07,   P= 0.74Þ, their levels of
estradiol ðr=−0.02,   P= 0.99Þ, or the ratio of TT to estradiol
ðr= 0.13,   P= 0.57Þ. The same qualitative results are obtained if
we restrict the analysis to participants in the placebo or testos-
terone group. Although we find no evidence of a relationship
between digit ratio and hormone levels in this dataset, these
analyses were performed with a subset of the participants (22 of
37), and the absence of a significant effect may, therefore, be
attributable to a lack of power.
Effects of Endogenous Estradiol. The effects of estradiol in the
placebo group were similar to those found in previous analyses
(Table S2), with estradiol levels reducing the effect of the
amount offered on the rates of punishment (β = −0.68, SE =
0.17, P < 0.001) and reward (β = −0.69, SE = 0.26, P = 0.006)
and the magnitude of reward chosen (Table S3). Estradiol levels
in the placebo group did not influence choices of punishment
magnitude (Table S3).
Reaction Times. Treatment with testosterone had no effect on
participants’ reaction times in the UG task when choosing to
accept or reject the proposer’ offers or when choosing to punish,
do nothing, or reward. This absence of a reduction in reaction
times suggests that injection with testosterone did not render
participants more impulsive. Treatment also had no effect on
response speed when choosing the magnitude of reward. Par-
ticipants treated with testosterone were slower when choosing
the magnitude of punishment ðβ=−2.16,   SE= 0.78,   P= 0.006Þ.
This difference decreased with decreasing offer amount
ðβ=−0.53,   SE= 0.20,   P= 0.008Þ. However, it is not possible to
determine whether these effects on reaction time when choosing
the magnitude of punishment are directly attributable to treatment
or the greater frequency with which participants in the testoster-
one group chose to punish the proposer (Fig. S5 and Table S5).
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Questionnaire Measures. To determine whether the effects of treat-
ment on participants’ choices were driven by testosterone-induced
biasing of the participants’ judgments of the proposers, we analyzed
participants’ ratings of the proposers’ faces. We found no effects of
treatment on participants’ ratings of the proposers’ trustworthiness,
dominance, frustration, angriness, friendliness, happiness, and at-
tractiveness made immediately before and after performing the UG
task. We found an effect of treatment on the Machiavellianism
subscale of the IPIP, such that the average change in the score of
participants in the placebo group (M = 1.44, SD = 2.62) after
treatment were greater [t(35.36) = 2.16, P = 0.04, two tailed)] than
that of those in the treatment group (M = −0.65, SD = 3.34). This
effect does not survive a Holm–Bonferroni multiple comparisons
correction for the number of subscales within the questionnaire. We
found no effects of treatment on the dominance, anger, emotional
stability, leadership, empathy, risk-taking, anxiety, conformity, social
confidence, fun-seeking, drive, and reward-responsiveness subscales
of the IPIP; the tension, depression, anger, fatigue, confusion, vigor,
or total mood disturbance subscales of the POMS; the psychoticism,
extraversion, neuroticism, or lie subscales of the EPQ-R; the SADI;
the BDI; the BAI; or the Mach IV.
Fig. S1. Testosterone levels. Box plot summarizing serum concentrations of TT at screening (preinjection) and the time of behavioral testing (postinjection) in
the placebo (pale green) and testosterone (dark green) groups. Box centers correspond to median values, box bottoms and tops correspond to the first and
third quartiles respectively, and whiskers represent the maximum and minimum concentrations. Pre- and postinjection testosterone levels did not differ
significantly in the placebo group (Mann–Whitney U = 162, P = 0.64, two tailed), but in the treatment group, postinjection levels were significantly elevated
(Mann-Whitney U = 4, P < 0.001, one sided).
Fig. S2. Rates of offer acceptance. Bar plot of participants’ average acceptance rates as a function of offer amount for the placebo (pale green) and tes-
tosterone (dark green) groups. Offer acceptance was not influenced by treatment.
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Fig. S3. Effects of participants’ beliefs. (A) Bar plot of participants’ average acceptance rates as a function of offer amount for participants who believed that
they had received placebo (pale green) and testosterone (dark green). Participants’ beliefs about treatment interacted with offer amount
ðβ=0.31,   SE= 0.13,   P = 0.02Þ, such that participants who believed that they had received testosterone (n = 6) were more likely to reject low offers than those
who believed that they had received placebo (n = 34). (B) Bar plot of the average magnitudes of reward (blue) and punishment (red) that participants chose as
a function of offer amount for participants who believed that they had received placebo (pale) and testosterone (dark). Participants who believed that they
had received testosterone reciprocated generous offers with rewards of lesser magnitude than those who believed that they had received placebo
ðβ=−0.18,   SE= 0.08,   P = 0.03Þ. The effect of participants’ treatment beliefs on punishment magnitude was not significant. All error bars represent SEM. Be-
lieved P, believed placebo; believed T, believed testosterone.
Fig. S4. High testosterone levels in the placebo group were associated with more frequent punishment and reward. Bar plot of the proportion of choices to
reward (blue) and punish (red) the proposer as a function of offer amount for participants in the placebo group with high (dark) and low (pale) testosterone as
determined by a median split. Rates of both punishment ðβ= 26.10,   SE= 9.41,   P = 0.006Þ and reward ðβ= 32.02,   SE= 11.72,   P = 0.007Þ increased significantly
with testosterone. High T, high testosterone; low T, low testosterone.
Dreher et al. www.pnas.org/cgi/content/short/1608085113 4 of 8
Table S1. Regressions of choices to accept/reject proposers’ offers
Regressor
Binary probit (accept offer = 1,
reject offer = 0)
Group Hormone
Intercept 3.21*** (0.43) 4.56** (1.41)
Offer amount† 0.93*** (0.07) 0.75** (0.24)
Treatment group‡ −0.24 (0.56)
Treatment group × offer amount −0.09 (0.08)
Belief§ −0.49 (0.77) −0.33 (0.85)
Belief × offer amount 0.31* (0.13) 0.62** (0.19)
T{ 1.42 (1.34)
T × offer amount −0.18 (0.19)
E# −0.79 (0.74)
E × offer amount 0.04 (0.10)
TBaselinek −4.88 (5.04)
TBaseline × offer amount 0.72 (0.82)
β-Coefficients (SEs) from mixed effects probit models with random partic-
ipant-level intercept. Models group (n = 40) and hormone (n = 37) include
participants from both the placebo and testosterone groups.
***P < 0.001.
**P < 0.01.
†Centered at mean (V6).
‡Testosterone = 1, placebo = 0.
§Believed testosterone = 1, believed placebo = 0.
*P < 0.05.
{TT (nanomoles per liter × 100) at Appointment 4.
#Estradiol (picomoles per liter × 100) at Appointment 4.
kTT (nanomoles per liter × 100) at Appointment 2.
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Fig. S5. Reaction times. Line graphs of average reaction times (RT) in the placebo (pale green) and testosterone (dark green) groups as a function of offer
amount when participants chose (A) whether to accept/reject offers; (B) whether to punish, do nothing to, or reward proposers; (C) what magnitude of
punishment to impose; or (D) what magnitude of reward to impose. Shadow represents SEM. Points without shadows represent offer amounts for which only a
single participant responded, thereby resulting in an SEM of zero. The reaction times of participants treated with testosterone differed only when choosing the
magnitude of punishment, when they were slower for average-sized offers ðβ=−2.16,   SE= 0.78,   P = 0.006Þ. This difference between the groups decreased
with decreasing offer amount ðβ=−0.53,   SE= 0.20,   P = 0.008Þ. These differences in reaction time may not be a direct effect of treatment but may instead be
attributable to the greater frequency with which participants in the testosterone group chose to punish the proposer.
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Table S3. Regressions of choices to punish for unfair and fair offers
Regressor
Binary probit (punish = 1, do nothing = 0, reward = 0)
Offer amounts < V6 Offer amounts ≥ V6
Intercept −0.43 (0.25) −4.88*** (1.20)
Offer amount† −0.34*** (0.07) 0.75 (0.24)
Treatment group‡ 0.25 (0.32) 1.40 (0.90)
Treatment group × offer amount 0.26*** (0.07) −0.18 (0.33)
Belief§ −0.13 (0.45)
Belief × offer amount −0.22* (0.10)
β-Coefficients (SEs) from mixed effects binary probit models (n = 40) of choices to punish (coded as one) vs. do
nothing or reward (coded as zero) with random participant-level intercept. Separate regressions were carried
out on choices in response to unfair offers (<V6) and fair offers (≥V6). Only one participant who believed that
he had received testosterone punished offers ≥V6. Regressors representing participants’ beliefs about treat-
ment were, therefore, omitted, because their effects cannot be estimated.
***P < 0.001.
†Centered at mean.
‡Testosterone = 1, placebo = 0.
§Believed testosterone = 1, believed placebo = 0; testosterone (nanomoles per liter × 100) at Appointment 2.
*P < 0.05.
Table S4. Regressions of choices of punishment amount and reward amount
Regressor
Reward amount linear regression Punishment amount linear regression
Group Hormone Placebo Group Hormone Placebo
Intercept 2.11*** (0.30) 0.21 (1.03) −0.55 (1.80) −1.92*** (0.52) 0.19 (1.70) −2.83 (3.50)
Offer amount† 0.41*** (0.05) 0.82*** (0.20) 1.56*** (0.33) 0.96*** (0.11 1.19*** (0.35 0.85 (0.72)
Group‡ 0.11 (0.39) −0.84 (0.64)
Group × offer amount 0.15* (0.07) 0.01 (0.13)
Belief§ −0.16 (0.55) 0.01 (0.62) 0.22 (0.80) 0.87 (0.97) 0.29 (1.12) 1.18 (2.01)
Belief × offer amount −0.18* (0.08) −0.17 (0.10) −0.30* (0.14) −0.20 (0.21) −0.46 (0.25) −0.32 (0.51)
T{ −0.46 (0.85) 4.29 (12.66) 4.00** (1.47) −13.59 (22.06)
T × offer amount 0.46** (0.16 −1.34 (2.78) 0.85** (0.26) −4.30 (4.88)
E# 0.83 (0.58) 1.45 (1.49) −2.29** (0.82) 1.27 (2.85)
E × offer amount −0.33** (0.13) −0.80* (0.34) −0.33* (0.14) 0.65 (0.76)
TBaseline
k 4.51 (3.43) −0.99 (6.03) −4.31 (6.33) 11.12 (12.22)
TBaseline × offer amount −0.22 (0.63) 0.56 (1.22) −0.34 (1.30) 1.58 (2.70)
β-Coefficients (SEs) from mixed effects linear models with random participant-level intercept. Models group (n = 40) and hormone
(n = 37) include participants from both the placebo and testosterone groups, whereas model placebo (n = 17) includes only participants
from the placebo group.
***P < 0.001.
†Centered at mean (V6).
‡Testosterone = 1, placebo = 0.
*P < 0.05.
§Believed testosterone = 1, believed placebo = 0.
{TT (nanomoles per liter × 100) at Appointment 4.
**P < 0.01.
#Estradiol (picomoles per liter × 100) at Appointment 4.
kTT (nanomoles per liter × 100) at Appointment 2.
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Table S5. Regressions of response speeds
Regressor Accept/reject Punish/do nothing/reward Punish magnitude† Reward magnitude
Intercept 9.96e-1*** (6.08e-2) 1.58*** (8.06e-2) 3.44*** (0.65) 1.91*** (0.29)
Offer amount‡ 3.84e-2*** (3.28e-3) −1.07e-3 (7.61e-3) 0.43* (0.17) 0.05 (0.04)
jOffer amountj§ −2.68e-2*** (6.35e-3) −1.02e-2 (1.46e-2) −0.08 (0.08)
Group{ 4.96e-2 (7.87e-2) −1.35e-2 (1.05e-1) −2.16** (0.78) −0.36 (0.37)
Group × offer amount 8.69e-4 (4.28e-3) 1.10e-2 (9.91e-3) −0.53** (0.20) 0.01 (0.07)
Group × joffer amountj 8.25e-3 (8.28e-3) −1.79e-2 (1.91e-2) 0.14 (0.10)
Belief# 9.68e-2 (1.10e-1) 1.65e-1 (1.46e-1; 0.51) 7.21*** (1.24) 0.40 (0.51)
Belief × offer amount 1.38e-2* (5.90e-3) 3.49e-2* (1.36e-2) 1.91*** (0.33) 0.15* (0.08)
Belief × joffer amountj 1.76e-3 (1.15e-2) 2.00e-2 (2.63e-2) 0.06 (0.02)
β-Coefficients (SEs) from mixed effects linear regressions with random participant-level intercept of response speeds (the inverse of
reaction times) for choices to accept or reject; choices to punish, do nothing, or reward; and choices of punishment and reward
magnitude (n = 40).
†jOffer amountj regressor omitted because of collinearity with offer amount regressor.
***P < 0.001.
‡Centered at mean (V6).
*P < 0.05.
§Centered at mean (V6) and absolute valued.
{Testosterone = 1, placebo = 0.
**P < 0.01.
#Believed testosterone = 1, believed placebo = 0.
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